Key statistics
On Monday, Amylyx Pharmaceuticals Inc (AMLX:NSQ) closed at 2.91, 84.76% above the 52 week low of 1.58 set on Jun 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.23 |
---|---|
High | 3.34 |
Low | 2.88 |
Bid | 2.87 |
Offer | 2.92 |
Previous close | 3.10 |
Average volume | 1.57m |
---|---|
Shares outstanding | 68.08m |
Free float | 58.31m |
P/E (TTM) | -- |
Market cap | 211.06m USD |
EPS (TTM) | -2.45 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
- Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
- Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
- Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
- Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
- Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
More ▼